Lola Fashoyin-Aje

Lola Fashoyin-Aje is a prominent figure in the field of cellular and genetic therapies, having recently directed the office responsible for evaluating these therapies at the U.S. Food and Drug Administration (FDA). She has been instrumental in the approval of groundbreaking treatments for advanced melanoma and metastatic sarcoma, emphasizing the promise of innovative immunotherapies. Her insights have highlighted the complexities and costs associated with these therapies, as well as the need for oncologists to understand their potential applications even in settings lacking access to such advanced treatments.